SORA

Advancing, promoting and sharing knowledge of health through excellence in teaching, clinical practice and research into the prevention and treatment of illness

Intellectual enrichment and genetic modifiers of cognition and brain volume in Huntington's disease.

Papoutsi, M; Flower, M; Hensman Moss, DJ; Holmans, P; Estevez-Fraga, C; Johnson, EB; Scahill, RI; Rees, G; Langbehn, D; Tabrizi, SJ; et al. Papoutsi, M; Flower, M; Hensman Moss, DJ; Holmans, P; Estevez-Fraga, C; Johnson, EB; Scahill, RI; Rees, G; Langbehn, D; Tabrizi, SJ; Track-HD Investigators (2022) Intellectual enrichment and genetic modifiers of cognition and brain volume in Huntington's disease. Brain Commun, 4 (6). fcac279. ISSN 2632-1297 https://doi.org/10.1093/braincomms/fcac279
SGUL Authors: Hensman Moss, Davina Jane

[img]
Preview
PDF Published Version
Available under License Creative Commons Attribution.

Download (1MB) | Preview
[img]
Preview
PDF (Supplementary data) Published Version
Available under License Creative Commons Attribution.

Download (2MB) | Preview

Abstract

An important step towards the development of treatments for cognitive impairment in ageing and neurodegenerative diseases is to identify genetic and environmental modifiers of cognitive function and understand the mechanism by which they exert an effect. In Huntington's disease, the most common autosomal dominant dementia, a small number of studies have identified intellectual enrichment, i.e. a cognitively stimulating lifestyle and genetic polymorphisms as potential modifiers of cognitive function. The aim of our study was to further investigate the relationship and interaction between genetic factors and intellectual enrichment on cognitive function and brain atrophy in Huntington's disease. For this purpose, we analysed data from Track-HD, a multi-centre longitudinal study in Huntington's disease gene carriers and focused on the role of intellectual enrichment (estimated at baseline) and the genes FAN1, MSH3, BDNF, COMT and MAPT in predicting cognitive decline and brain atrophy. We found that carrying the 3a allele in the MSH3 gene had a positive effect on global cognitive function and brain atrophy in multiple cortical regions, such that 3a allele carriers had a slower rate of cognitive decline and atrophy compared with non-carriers, in agreement with its role in somatic instability. No other genetic predictor had a significant effect on cognitive function and the effect of MSH3 was independent of intellectual enrichment. Intellectual enrichment also had a positive effect on cognitive function; participants with higher intellectual enrichment, i.e. those who were better educated, had higher verbal intelligence and performed an occupation that was intellectually engaging, had better cognitive function overall, in agreement with previous studies in Huntington's disease and other dementias. We also found that intellectual enrichment interacted with the BDNF gene, such that the positive effect of intellectual enrichment was greater in Met66 allele carriers than non-carriers. A similar relationship was also identified for changes in whole brain and caudate volume; the positive effect of intellectual enrichment was greater for Met66 allele carriers, rather than for non-carriers. In summary, our study provides additional evidence for the beneficial role of intellectual enrichment and carrying the 3a allele in MSH3 in cognitive function in Huntington's disease and their effect on brain structure.

Item Type: Article
Additional Information: © The Author(s) 2022. Published by Oxford University Press on behalf of the Guarantors of Brain. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
Keywords: Huntington’s disease, MSH3, brain-derived neurotrophic factor, cognitive modifiers, intellectual enrichment
SGUL Research Institute / Research Centre: Academic Structure > Molecular and Clinical Sciences Research Institute (MCS)
Journal or Publication Title: Brain Commun
ISSN: 2632-1297
Language: eng
Dates:
DateEvent
31 October 2022Published
27 October 2022Accepted
Publisher License: Creative Commons: Attribution 4.0
Projects:
Project IDFunderFunder ID
UNSPECIFIEDHuntington's Disease Society of Americahttp://dx.doi.org/10.13039/100000887
UNSPECIFIEDUK Dementia Research Institutehttp://dx.doi.org/10.13039/501100017510
UNSPECIFIEDCHDI Foundationhttp://dx.doi.org/10.13039/100005725
PubMed ID: 36519153
Go to PubMed abstract
URI: https://openaccess.sgul.ac.uk/id/eprint/115081
Publisher's version: https://doi.org/10.1093/braincomms/fcac279

Actions (login required)

Edit Item Edit Item